News & Media

July 11, 2022
Optimizing Process Development Early – A critical factor in successful viral vector scale up and large scale manufacture
February 28, 2022
Observed every year on the last day in February, Rare Disease Day works to raise awareness for rare diseases and...
February 11, 2022
Every day here at Andelyn Biosciences is Women in Science Day! We are proud that 50% of our scientists on...
February 8, 2022
Gene therapies offer an unprecedented ability to treat — and even cure — genetic diseases, and their potential spanning diverse...
November 11, 2021
Andelyn Biosciences has established a unique network of industry experts across the entire development and commercialization spectrum. In addition to...
October 22, 2021
Andelyn Biosciences is building the best cell and gene therapy team in spite of a talent shortage and competitive talent...
September 23, 2021
The analytical requirements for viral vectors used to deliver gene therapies are complex and constantly evolving. The keys to success,...
September 16, 2021
The number of gene therapy candidates in development is growing rapidly, with many advancing toward late-stage trials. The majority of...
August 23, 2021
Abstract: Andelyn Biosciences, a full-spectrum gene therapy CDMO organization that supports clients from preclinical studies through phase III trials, originally...
June 20, 2021
Adeno-associated viruses (AAV) are small viruses that can infect humans and other primate species. The particularity about AAV is that...
February 15, 2021
“What’s in a name?” the saying goes. In this case, much more than meets the eye. Andelyn Biosciences is much...